Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of [LC]: RECOVER-VITAL, 2026, Zimmerman+

[forestglip]

Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL

Spoiler: Authors

Kanecia O Zimmerman, Richard Whitley, Sean O’Brien, David R Walt, Bruce D Levy, Christine Maughan, Marta Cerda, Rachel Olson, Lucinda Bateman, Cyndya A Shibao, Barry Make, David Knopman, Susan Redline, Leonard A Jason, Mehul S Suthar, Phillip Low, Tracy L Nolen, Craig Reist, Lisa Berdan, Lindsey R Baden

Background
Long COVID, the chronic sequela of SARS-CoV-2 infection, has affected millions of people worldwide. However, its pathogenesis and treatment remain unknown. To address this critical gap, the National Institutes of Health (NIH) developed the Researching COVID to Enhance Recovery (RECOVER) Initiative that included the Viral Persistence and Reactivation, and Immune Dysregulation (RECOVER-VITAL) study as one of the first of five NIH-sponsored, integrated platform protocols to support the rigorous and rapid investigation of potential interventions for Long COVID.

Methods
Experts across academia, the NIH, and the community of patients and caregivers were brought together to design the RECOVER-VITAL protocol. We present the challenges and rationale underpinning critical components of this protocol and provide evidence for use of the platform for efficient execution of current and future Long COVID clinical trials.

Facets of the RECOVER-VITAL protocol, including inclusion criteria, intervention groups, study procedures, investigation of biomarkers, and endpoints, were carefully crafted to advance the current and future science and operations of Long COVID clinical trials, particularly in the absence of existing data.

The initial trial within the RECOVER-VITAL platform evaluated two durations of an antiviral drug, nirmatrelvir/ritonavir, to test the proposed etiology of viral persistence on the Long COVID symptom clusters of autonomic dysfunction, cognitive dysfunction, and exercise intolerance. The primary outcome measures were patient-reported, and secondary outcomes included performance-based measures for each of the symptom clusters of interest.

Conclusions
The RECOVER-VITAL platform protocol has substantial implications for the design and conduct of future Long COVID clinical trials.

Web | Clinical Trials | Paywall

 

[Hutan]

Unfortunately the Conclusions don't actually tell us what the substantial implications for the design and conduct of future Long COVID clinical trials are. I guess they want us to pay for access?

I'm not sure how that works. The trial was done by the NIH, presumably funded by US government funds? I can't imagine the 'community of patients and caregivers brought together' with the academics and NIH staff were well paid for their time. Similarly, I doubt the trial participants were well paid for being guinea pigs.

Long COVID is an international public health crisis and presumably this paper aims to improve future trials, in a field where low quality trials has been the norm. And yet, Sage Journals 'Clinical Trials' wants to charge people 32 pounds to have a look at it?

The primary outcome measures were patient-reported

They say it proudly like it's a good thing. Perhaps it is ok if the study was blinded and/or the secondary measures are objective. I can't say from the information in the abstract.

 

[V.R.T.]

The RECOVER-VITAL platform protocol has substantial implications for the design and conduct of future Long COVID clinical trials.

It's been five f-king years since RECOVER was announced! Five years. And they are giving themselves a congratulatory pat on the back for their trial design having achieved absolutely sweet f-a.

They have squandered a billion and a half dollars on treatments that were almost certain to fail and useless studies about how many long haulers report headaches or whatever. What happened to all the biobanking work? Why haven't they done a GWAS? Why are they not investigating the interesting findings that need replicating?

It's a collosal mess.

 

[SNT Gatchaman]

RECOVER-VITAL was designed with the intention of identifying potential biomarkers within the context of a clinical trial. Participants were requested to provide several biological samples, including nasal swabs, stool, and blood, at four scheduled timepoints, including baseline, middle of intervention, end of intervention (day 25), and end of study (day 180). […] participants were also encouraged to provide optional blood samples at three additional timepoints (days 45, 60, and 120).

Some analyses of samples, including basic inflammatory markers and potential indicators of antigenemia, were planned to occur during and shortly after the trial using known assays […] However, the majority of blood samples were stored in a central biorepository for future analyses as technology advances to aid in the identification of viral persistence. The Simoa SARS-CoV-2 assay will be used retrospectively to detect the presence of viral antigen at baseline, thus allowing an analysis of the intervention by presence of viral antigen, and the control group will allow us to define the variability of antigen detection over time.

Biomarker analyses will be exploratory and focused on markers of viral persistence and inflammation. Planned analyses include descriptive summaries and group comparisons of biomarker levels over time, including antigenemia, inflammatory markers (e.g. high-sensitivity C-reactive protein), and coagulation parameters.

While the STOP-PASC (Selective Trial Of Paxlovid for PASC) and PAX LC (Paxlovid for Long COVID) trials did not demonstrate a positive effect on Long COVID, the RECOVER-VITAL study remains a critical addition to the field and still has potential for demonstrating effect because: (1) it does not assume that all Long COVID behaves the same and allows potential differentiation between Long COVID that manifests as one of the three symptom clusters of interest; (2) it uses cluster-specific endpoints that will enable understanding of improving in symptoms; (3) the dose-ranging design allows exploration of dosing longer than 15 days; and (4) its large sample size will enable evaluation of heterogeneity of treatment effect, including the potential effect of nirmatrelvir/ritonavir within participants who have evidence of viral persistence.

All of these characteristics of RECOVERVITAL are critical for moving the field forward, and results of the study will cover many of the remaining critical questions for use of nirmatrelvir/ritonavir in Long COVID. Moreover, the platform structure and supporting infrastructure of RECOVER-VITAL are well primed for the efficient addition of antivirals, antiinflammatories, and coagulation modulators for future investigation.

 

[V.R.T.]

Biomarker analyses will be exploratory and focused on markers of viral persistence and inflammation.

Because they haven't wasted enough time looking for what almost certainly isn't there.